Alpha Emitter MarketSize and Trends

Global alpha emitter market is estimated to be valued at US$ 1,331.0 million in 2023 and is expected to exhibit a CAGR of 10.3 % during the forecast period (2023-2030).

Increase in the collaborations among key players to expand their product portfolio is expected to drive the growth of the global alpha emitter market over the forecast period. Moreover, increase in the investment in research and development of alpha emitter products is expected to drive the growth of the global alpha emitter market over the forecast period.

Global Alpha Emitter Market - Driver

Increasing Prevalence of Cancer Worldwide

Increasing prevalence of different types of cancer such as breast cancer, prostate cancer, neuroendocrine tumors, ovarian cancer, and others is expected to drive the growth of global alpha emitter market over the forecast period. For instance according to data published by the World Health Organization, in February 2022, cancer is a prominent cause of death worldwide, accounting for about 10 million fatalities in 2020, or nearly one in six deaths.

Increasing Research and Development Activities

Increasing research and development by key market players for the discovery of new treatment such as alpha radioligand therapy to treat cancer is expected to drive the global alpha emitter market over the forecast period. For instance, on January 4, 2023, Orano Med, a pharmaceutical company, announced that the 212Pb-GRPR, an alpha radioligand therapy with lead-212, for patients with solid tumors that express the gastrin-releasing peptide receptor, has dosed its first patient in a Phase 1 clinical trial. 212Pb-GRPR is the targeted alpha therapy aiming gastrin-releasing peptide receptor, a protein found on the surface of cells that is expressed in prostate cancer, lung cancer, breast cancer and other solid tumors

Global Alpha Emitter Market Segmentation:

Global alpha emitter market is segmented into Type of Radionuclide, source, application and end user.

Bases on Type of Radionuclide, the market is segmented into Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213, and others. Out of which, Actinium (Ac-225) is expected to dominate the segment during the forecast period due to increasing research and development for the treatment of metastatic castration-resistant prostate cancer. For instance, according to an article published in August 2022, by Radiation journal, a researcher from Kindai University, Japan, has investigated into the optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer and concluded that early administration of Ra-223 was significantly associated with improved OS and that it might be beneficial to administer Ra-223 before novel hormonal or anticancer agents.

Based on Source, the market is segmented into natural sources and artificially produced sources. Out of which, natural sources is expected to dominate the segment to dominate the global alpha emitter market forecast period. The natural radionuclides include primordial radioactive elements in the earth's crust, its radioactive decay products, and the radionuclides produced from the bombardment of stable nuclides by cosmic radiation. Alpha radiation is a type of energy that is emitted when radioactive elements decay or break down. Uranium and thorium are radioactive elements that are found naturally in the Earth’s crust. These two elements changes their form over billions of years, and this leads to the production of decay products named radon and radium. Energy is released during this process.

Based on Application, the market is segmented into bone metastases, prostate cancer, neuroendocrine tumor, ovarian cancer and others. Out of which, bone metastases is expected to dominate the segment due increasing research and development in targeted alpha-particle emitting radiopharmaceuticals as therapy for prostate cancer patients with bone metastases. For instance, according to an article published in April 2021, by the National Center for Biotechnology Information, researchers form Wake Forest University Health Sciences, North Carolina, U.S., and the University of Iowa, U.S., reported that radium-223 dichloride, an alpha-particle-emitting radiopharmaceutical, improves the overall survival of prostate cancer patients with bone metastases.